UniProtKB - P01889 (HLAB_HUMAN)
(max 400 entries)
Your basket is currently empty. i <p>When browsing through different UniProt proteins, you can use the 'basket' to save them, so that you can back to find or analyse them later.<p><a href='/help/basket' target='_top'>More...</a></p>
Select item(s) and click on "Add to basket" to create your own collection here
(400 entries max)
>sp|P01889|HLAB_HUMAN HLA class I histocompatibility antigen, B alpha chain OS=Homo sapiens OX=9606 GN=HLA-B PE=1 SV=3 MLVMAPRTVLLLLSAALALTETWAGSHSMRYFYTSVSRPGRGEPRFISVGYVDDTQFVRF DSDAASPREEPRAPWIEQEGPEYWDRNTQIYKAQAQTDRESLRNLRGYYNQSEAGSHTLQ SMYGCDVGPDGRLLRGHDQYAYDGKDYIALNEDLRSWTAADTAAQITQRKWEAAREAEQR RAYLEGECVEWLRRYLENGKDKLERADPPKTHVTHHPISDHEATLRCWALGFYPAEITLT WQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEP SSQSTVPIVGIVAGLAVLAVVVIGAVVAAVMCRRKSSGGKGGSYSQAACSDSAQGSDVSL TACommunity curation ()Add a publicationFeedback
Protein
HLA class I histocompatibility antigen, B alpha chain
Gene
HLA-B
Organism
Homo sapiens (Human)
Status
Reviewed-Annotation score:
Annotation score:5 out of 5
<p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the 'correct annotation' for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p>-Experimental evidence at protein leveli <p>This indicates the type of evidence that supports the existence of the protein. Note that the 'protein existence' evidence does not give information on the accuracy or correctness of the sequence(s) displayed.<p><a href='/help/protein_existence' target='_top'>More...</a></p>Select a section on the left to see content.
<p>This section provides any useful information about the protein, mostly biological knowledge.<p><a href='/help/function_section' target='_top'>More...</a></p>Functioni
Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:25808313, PubMed:29531227, PubMed:9620674, PubMed:23209413). May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity (PubMed:7743181, PubMed:18991276). Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells (PubMed:29531227, PubMed:9620674, PubMed:24600035). Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via constitutive proteasome and IFNG-induced immunoproteasome (PubMed:23209413). Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9 (PubMed:25808313, PubMed:29531227).7 Publications
<p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More...</a></p> Manual assertion based on experiment ini
- Ref.54"Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes."
Barber L.D., Gillece-Castro B., Percival L., Li X., Clayberger C., Parham P.
Curr. Biol. 5:179-190(1995) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*07:02; B*54:01; B*55:01; B*56:01 AND B*67:01). - Ref.57"HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading."
Peh C.A., Burrows S.R., Barnden M., Khanna R., Cresswell P., Moss D.J., McCluskey J.
Immunity 8:531-542(1998) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*08:01; B*27:05 AND B*44:02), INTERACTION WITH TAP1-TAP2, SUBCELLULAR LOCATION. - Ref.63"Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype."
Hillen N., Mester G., Lemmel C., Weinzierl A.O., Mueller M., Wernet D., Hennenlotter J., Stenzl A., Rammensee H.G., Stevanovic S.
Eur. J. Immunol. 38:2993-3003(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*18:01; B*40:01; B*41:01; B*44:02; B*45:01; B*47:01; B*49:01 AND B*50:01). - Ref.69"Rapid antigen processing and presentation of a protective and immunodominant HLA-B*27-restricted hepatitis C virus-specific CD8+ T-cell epitope."
Schmidt J., Iversen A.K., Tenzer S., Gostick E., Price D.A., Lohmann V., Distler U., Bowness P., Schild H., Blum H.E., Klenerman P., Neumann-Haefelin C., Thimme R.
PLoS Pathog. 8:E1003042-E1003042(2012) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION. - Ref.80"Molecular basis of a dominant T cell response to an HIV reverse transcriptase 8-mer epitope presented by the protective allele HLA-B*51:01."
Motozono C., Kuse N., Sun X., Rizkallah P.J., Fuller A., Oka S., Cole D.K., Sewell A.K., Takiguchi M.
J. Immunol. 192:3428-3434(2014) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.99 ANGSTROMS) OF 25-300 (ALLELE B*51:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE B*51:01). - Ref.81"A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape."
Kloverpris H.N., Cole D.K., Fuller A., Carlson J., Beck K., Schauenburg A.J., Rizkallah P.J., Buus S., Sewell A.K., Goulder P.
Retrovirology 12:20-20(2015) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.59 ANGSTROMS) OF 25-300 (ALLELE B*07:02) IN COMPLEX WITH B2M AND HIV-1 PEPTIDES, DISULFIDE BOND, FUNCTION (ALLELE B*07:02), DOMAIN. - Ref.82"Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide."
Chan K.F., Gully B.S., Gras S., Beringer D.X., Kjer-Nielsen L., Cebon J., McCluskey J., Chen W., Rossjohn J.
Nat. Commun. 9:1026-1026(2018) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) (ALLELE B*07:02) IN COMPLEX WITH B2M AND PEPTIDE, DISULFIDE BOND, INTERACTION WITH TCR, FUNCTION (ALLELE B*07:02).
Allele B*07:02: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and mainly a Leu anchor residue at the C-terminus (PubMed:7743181). Presents a long peptide (APRGPHGGAASGL) derived from the cancer-testis antigen CTAG1A/NY-ESO-1, eliciting a polyclonal CD8-positive T cell response against tumor cells (PubMed:29531227). Presents viral epitopes derived from HIV-1 gag-pol (TPQDLNTML) and Nef (RPQVPLRPM) (PubMed:25808313). Presents an immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein (SPRWYFYYL) (PubMed:32887977). Displays self-peptides including a peptide derived from the signal sequence of HLA-DPB1 (APRTVALTA) (PubMed:7743181).4 Publications
Manual assertion based on experiment ini
- Ref.54"Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes."
Barber L.D., Gillece-Castro B., Percival L., Li X., Clayberger C., Parham P.
Curr. Biol. 5:179-190(1995) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*07:02; B*54:01; B*55:01; B*56:01 AND B*67:01). - Ref.76"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19."
Oxford Immunology Network Covid-19 Response T cell Consortium, ISARIC4C Investigators
Peng Y., Mentzer A.J., Liu G., Yao X., Yin Z., Dong D., Dejnirattisai W., Rostron T., Supasa P., Liu C., Lopez-Camacho C., Slon-Campos J., Zhao Y., Stuart D.I., Paesen G.C., Grimes J.M., Antson A.A., Bayfield O.W. , Hawkins D.E.D.P., Ker D.S., Wang B., Turtle L., Subramaniam K., Thomson P., Zhang P., Dold C., Ratcliff J., Simmonds P., de Silva T., Sopp P., Wellington D., Rajapaksa U., Chen Y.L., Salio M., Napolitani G., Paes W., Borrow P., Kessler B.M., Fry J.W., Schwabe N.F., Semple M.G., Baillie J.K., Moore S.C., Openshaw P.J.M., Ansari M.A., Dunachie S., Barnes E., Frater J., Kerr G., Goulder P., Lockett T., Levin R., Zhang Y., Jing R., Ho L.P., Cornall R.J., Conlon C.P., Klenerman P., Screaton G.R., Mongkolsapaya J., McMichael A., Knight J.C., Ogg G., Dong T.
Nat. Immunol. 0:0-0(2020) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*07:02; B*27:05 AND B*40:01). - Ref.81"A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape."
Kloverpris H.N., Cole D.K., Fuller A., Carlson J., Beck K., Schauenburg A.J., Rizkallah P.J., Buus S., Sewell A.K., Goulder P.
Retrovirology 12:20-20(2015) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.59 ANGSTROMS) OF 25-300 (ALLELE B*07:02) IN COMPLEX WITH B2M AND HIV-1 PEPTIDES, DISULFIDE BOND, FUNCTION (ALLELE B*07:02), DOMAIN. - Ref.82"Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide."
Chan K.F., Gully B.S., Gras S., Beringer D.X., Kjer-Nielsen L., Cebon J., McCluskey J., Chen W., Rossjohn J.
Nat. Commun. 9:1026-1026(2018) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) (ALLELE B*07:02) IN COMPLEX WITH B2M AND PEPTIDE, DISULFIDE BOND, INTERACTION WITH TCR, FUNCTION (ALLELE B*07:02).
Allele B*08:01: Presents to CD8-positive T cells viral epitopes derived from EBV/HHV-4 EBNA3 (QAKWRLQTL), eliciting cytotoxic T cell response.1 Publication
Manual assertion based on experiment ini
- Ref.57"HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading."
Peh C.A., Burrows S.R., Barnden M., Khanna R., Cresswell P., Moss D.J., McCluskey J.
Immunity 8:531-542(1998) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*08:01; B*27:05 AND B*44:02), INTERACTION WITH TAP1-TAP2, SUBCELLULAR LOCATION.
Allele B*13:02: Presents multiple HIV-1 epitopes derived from gag (RQANFLGKI, GQMREPRGSDI), nef (RQDILDLWI), gag-pol (RQYDQILIE, GQGQWTYQI) and rev (LQLPPLERL), all having in common a Gln residue at position 2 and mainly hydrophobic amino acids Leu, Ile or Val at the C-terminus. Associated with succesful control of HIV-1 infection.1 Publication
Manual assertion based on experiment ini
- Ref.62"Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes."
Honeyborne I., Prendergast A., Pereyra F., Leslie A., Crawford H., Payne R., Reddy S., Bishop K., Moodley E., Nair K., van der Stok M., McCarthy N., Rousseau C.M., Addo M., Mullins J.I., Brander C., Kiepiela P., Walker B.D., Goulder P.J.
J. Virol. 81:3667-3672(2007) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE B*13:02).
Allele B*18:01: Preferentially presents octomeric and nonameric peptides sharing a common motif, namely a Glu at position 2 and Phe or Tyr anchor residues at the C-terminus (PubMed:14978097, PubMed:23749632, PubMed:18991276). Presents an EBV/HHV-4 epitope derived from BZLF1 (SELEIKRY) (PubMed:23749632). May present to CD8-positive T cells an antigenic peptide derived from MAGEA3 (MEVDPIGHLY), triggering an anti-tumor immune response (PubMed:12366779). May display a broad repertoire of self-peptides with a preference for peptides derived from RNA-binding proteins (PubMed:14978097).4 Publications
Manual assertion based on experiment ini
- Ref.59"A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18."
Bilsborough J., Panichelli C., Duffour M.T., Warnier G., Lurquin C., Schultz E.S., Thielemans K., Corthals J., Boon T., van der Bruggen P.
Tissue Antigens 60:16-24(2002) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE B*18:01). - Ref.60"Toward a definition of self: proteomic evaluation of the class I peptide repertoire."
Hickman H.D., Luis A.D., Buchli R., Few S.R., Sathiamurthy M., VanGundy R.S., Giberson C.F., Hildebrand W.H.
J. Immunol. 172:2944-2952(2004) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE B*18:01). - Ref.63"Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype."
Hillen N., Mester G., Lemmel C., Weinzierl A.O., Mueller M., Wernet D., Hennenlotter J., Stenzl A., Rammensee H.G., Stevanovic S.
Eur. J. Immunol. 38:2993-3003(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*18:01; B*40:01; B*41:01; B*44:02; B*45:01; B*47:01; B*49:01 AND B*50:01). - Ref.70"HLA peptide length preferences control CD8+ T cell responses."
Rist M.J., Theodossis A., Croft N.P., Neller M.A., Welland A., Chen Z., Sullivan L.C., Burrows J.M., Miles J.J., Brennan R.M., Gras S., Khanna R., Brooks A.G., McCluskey J., Purcell A.W., Rossjohn J., Burrows S.R.
J. Immunol. 191:561-571(2013) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE B*18:01).
Allele B*27:05: Presents to CD8-positive T cells immunodominant viral epitopes derived from HCV POLG (ARMILMTHF), HIV-1 gag (KRWIILGLNK), IAV NP (SRYWAIRTR), SARS-CoV-2 N/nucleoprotein (QRNAPRITF), EBV/HHV-4 EBNA4 (HRCQAIRKK) and EBV/HHV-4 EBNA6 (RRIYDLIEL), confering longterm protection against viral infection (PubMed:19139562, PubMed:18385228, PubMed:15113903, PubMed:9620674, PubMed:32887977). Can present self-peptides derived from cytosolic and nuclear proteins. All peptides carry an Arg at position 2 (PubMed:1922338). The peptide-bound form interacts with NK cell inhibitory receptor KIR3DL1 and inhibits NK cell activation in a peptide-specific way, being particularly sensitive to the nature of the amino acid side chain at position 8 of the antigenic peptide (PubMed:8879234, PubMed:15657948). KIR3DL1 fails to recognize HLA-B*27:05 in complex with B2M and EBV/HHV-4 EBNA6 (RRIYDLIEL) peptide, which can lead to increased activation of NK cells during infection (PubMed:15657948). May present an altered repertoire of peptides in the absence of TAP1-TAP2 and TAPBPL (PubMed:9620674).7 Publications
Manual assertion based on experiment ini
- Ref.53"Identification of self peptides bound to purified HLA-B27."
Jardetzky T.S., Lane W.S., Robinson R.A., Madden D.R., Wiley D.C.
Nature 353:326-329(1991) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE B*27:05). - Ref.55"A p70 killer cell inhibitory receptor specific for several HLA-B allotypes discriminates among peptides bound to HLA-B*2705."
Peruzzi M., Wagtmann N., Long E.O.
J. Exp. Med. 184:1585-1590(1996) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE B*27:05). - Ref.57"HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading."
Peh C.A., Burrows S.R., Barnden M., Khanna R., Cresswell P., Moss D.J., McCluskey J.
Immunity 8:531-542(1998) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*08:01; B*27:05 AND B*44:02), INTERACTION WITH TAP1-TAP2, SUBCELLULAR LOCATION. - Ref.61"A mutation in the HLA-B*2705-restricted NP383-391 epitope affects the human influenza A virus-specific cytotoxic T-lymphocyte response in vitro."
Berkhoff E.G., Boon A.C., Nieuwkoop N.J., Fouchier R.A., Sintnicolaas K., Osterhaus A.D., Rimmelzwaan G.F.
J. Virol. 78:5216-5222(2004) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE B*27:05). - Ref.64"Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid."
Schneidewind A., Brockman M.A., Sidney J., Wang Y.E., Chen H., Suscovich T.J., Li B., Adam R.I., Allgaier R.L., Mothe B.R., Kuntzen T., Oniangue-Ndza C., Trocha A., Yu X.G., Brander C., Sette A., Walker B.D., Allen T.M.
J. Virol. 82:5594-5605(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE B*27:05). - Ref.65"Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response."
Dazert E., Neumann-Haefelin C., Bressanelli S., Fitzmaurice K., Kort J., Timm J., McKiernan S., Kelleher D., Gruener N., Tavis J.E., Rosen H.R., Shaw J., Bowness P., Blum H.E., Klenerman P., Bartenschlager R., Thimme R.
J. Clin. Invest. 119:376-386(2009) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE B*27:05). - Ref.77"Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705."
Stewart-Jones G.B., di Gleria K., Kollnberger S., McMichael A.J., Jones E.Y., Bowness P.
Eur. J. Immunol. 35:341-351(2005) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-300 (ALLELE B*27:05) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE B*27:05).
Allele B*40:01: Presents immunodominant viral epitopes derived from EBV/HHV-4 LMP2 (IEDPPFNSL) and SARS-CoV-2 N/nucleoprotein (MEVTPSGTWL), triggering memory CD8-positive T cell response (PubMed:18991276, PubMed:32887977). Displays self-peptides sharing a signature motif, namely a Glu at position 2 and a Leu anchor residue at the C-terminus (PubMed:18991276).2 Publications
Manual assertion based on experiment ini
- Ref.63"Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype."
Hillen N., Mester G., Lemmel C., Weinzierl A.O., Mueller M., Wernet D., Hennenlotter J., Stenzl A., Rammensee H.G., Stevanovic S.
Eur. J. Immunol. 38:2993-3003(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*18:01; B*40:01; B*41:01; B*44:02; B*45:01; B*47:01; B*49:01 AND B*50:01). - Ref.76"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19."
Oxford Immunology Network Covid-19 Response T cell Consortium, ISARIC4C Investigators
Peng Y., Mentzer A.J., Liu G., Yao X., Yin Z., Dong D., Dejnirattisai W., Rostron T., Supasa P., Liu C., Lopez-Camacho C., Slon-Campos J., Zhao Y., Stuart D.I., Paesen G.C., Grimes J.M., Antson A.A., Bayfield O.W. , Hawkins D.E.D.P., Ker D.S., Wang B., Turtle L., Subramaniam K., Thomson P., Zhang P., Dold C., Ratcliff J., Simmonds P., de Silva T., Sopp P., Wellington D., Rajapaksa U., Chen Y.L., Salio M., Napolitani G., Paes W., Borrow P., Kessler B.M., Fry J.W., Schwabe N.F., Semple M.G., Baillie J.K., Moore S.C., Openshaw P.J.M., Ansari M.A., Dunachie S., Barnes E., Frater J., Kerr G., Goulder P., Lockett T., Levin R., Zhang Y., Jing R., Ho L.P., Cornall R.J., Conlon C.P., Klenerman P., Screaton G.R., Mongkolsapaya J., McMichael A., Knight J.C., Ogg G., Dong T.
Nat. Immunol. 0:0-0(2020) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*07:02; B*27:05 AND B*40:01).
Allele B*41:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor residues at the C-terminus.1 Publication
Manual assertion based on experiment ini
- Ref.63"Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype."
Hillen N., Mester G., Lemmel C., Weinzierl A.O., Mueller M., Wernet D., Hennenlotter J., Stenzl A., Rammensee H.G., Stevanovic S.
Eur. J. Immunol. 38:2993-3003(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*18:01; B*40:01; B*41:01; B*44:02; B*45:01; B*47:01; B*49:01 AND B*50:01).
Allele B*44:02: Presents immunodominant viral epitopes derived from EBV/HHV-4 EBNA4 (VEITPYKPTW) and EBNA6 (AEGGVGWRHW, EENLLDFVRF), triggering memory CD8-positive T cell response (PubMed:9620674, PubMed:18991276). Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Phe, Tyr or Trp anchor residues at the C-terminus (PubMed:18991276).2 Publications
Manual assertion based on experiment ini
- Ref.57"HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading."
Peh C.A., Burrows S.R., Barnden M., Khanna R., Cresswell P., Moss D.J., McCluskey J.
Immunity 8:531-542(1998) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*08:01; B*27:05 AND B*44:02), INTERACTION WITH TAP1-TAP2, SUBCELLULAR LOCATION. - Ref.63"Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype."
Hillen N., Mester G., Lemmel C., Weinzierl A.O., Mueller M., Wernet D., Hennenlotter J., Stenzl A., Rammensee H.G., Stevanovic S.
Eur. J. Immunol. 38:2993-3003(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*18:01; B*40:01; B*41:01; B*44:02; B*45:01; B*47:01; B*49:01 AND B*50:01).
Allele B*45:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor residues at the C-terminus.1 Publication
Manual assertion based on experiment ini
- Ref.63"Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype."
Hillen N., Mester G., Lemmel C., Weinzierl A.O., Mueller M., Wernet D., Hennenlotter J., Stenzl A., Rammensee H.G., Stevanovic S.
Eur. J. Immunol. 38:2993-3003(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*18:01; B*40:01; B*41:01; B*44:02; B*45:01; B*47:01; B*49:01 AND B*50:01).
Allele B*46:01: Preferentially presents nonameric peptides sharing a signature motif, namely Ala and Leu at position 2 and Tyr, Phe, Leu, or Met anchor residues at the C-terminus. The peptide-bound form interacts with KIR2DL3 and inhibits NK cell cytotoxic response in a peptide-specific way.1 Publication
Manual assertion based on experiment ini
- Ref.75"The Intergenic Recombinant HLA-B*46:01 Has a Distinctive Peptidome that Includes KIR2DL3 Ligands."
Hilton H.G., McMurtrey C.P., Han A.S., Djaoud Z., Guethlein L.A., Blokhuis J.H., Pugh J.L., Goyos A., Horowitz A., Buchli R., Jackson K.W., Bardet W., Bushnell D.A., Robinson P.J., Mendoza J.L., Birnbaum M.E., Nielsen M., Garcia K.C., Hildebrand W.H., Parham P.
Cell Rep. 19:1394-1405(2017) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE B*46:01), INTERACTION WITH KIR2DL3.
Allele B*47:01: Displays self-peptides sharing a signature motif, namely an Asp at position 2 and Leu or Met anchor residues at the C-terminus.1 Publication
Manual assertion based on experiment ini
- Ref.63"Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype."
Hillen N., Mester G., Lemmel C., Weinzierl A.O., Mueller M., Wernet D., Hennenlotter J., Stenzl A., Rammensee H.G., Stevanovic S.
Eur. J. Immunol. 38:2993-3003(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*18:01; B*40:01; B*41:01; B*44:02; B*45:01; B*47:01; B*49:01 AND B*50:01).
Allele B*49:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ile or Val anchor residues at the C-terminus.1 Publication
Manual assertion based on experiment ini
- Ref.63"Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype."
Hillen N., Mester G., Lemmel C., Weinzierl A.O., Mueller M., Wernet D., Hennenlotter J., Stenzl A., Rammensee H.G., Stevanovic S.
Eur. J. Immunol. 38:2993-3003(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*18:01; B*40:01; B*41:01; B*44:02; B*45:01; B*47:01; B*49:01 AND B*50:01).
Allele B*50:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor residues at the C-terminus.1 Publication
Manual assertion based on experiment ini
- Ref.63"Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype."
Hillen N., Mester G., Lemmel C., Weinzierl A.O., Mueller M., Wernet D., Hennenlotter J., Stenzl A., Rammensee H.G., Stevanovic S.
Eur. J. Immunol. 38:2993-3003(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*18:01; B*40:01; B*41:01; B*44:02; B*45:01; B*47:01; B*49:01 AND B*50:01).
Allele B*51:01: Presents an octomeric HIV-1 epitope derived from gag-pol (TAFTIPSI) to the public TRAV17/TRBV7-3 TCR clonotype, strongly suppressing HIV-1 replication.1 Publication
Manual assertion based on experiment ini
- Ref.80"Molecular basis of a dominant T cell response to an HIV reverse transcriptase 8-mer epitope presented by the protective allele HLA-B*51:01."
Motozono C., Kuse N., Sun X., Rizkallah P.J., Fuller A., Oka S., Cole D.K., Sewell A.K., Takiguchi M.
J. Immunol. 192:3428-3434(2014) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.99 ANGSTROMS) OF 25-300 (ALLELE B*51:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE B*51:01).
Allele B*54:01: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Ala anchor residue at the C-terminus.1 Publication
Manual assertion based on experiment ini
- Ref.54"Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes."
Barber L.D., Gillece-Castro B., Percival L., Li X., Clayberger C., Parham P.
Curr. Biol. 5:179-190(1995) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*07:02; B*54:01; B*55:01; B*56:01 AND B*67:01).
Allele B*55:01: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Ala anchor residue at the C-terminus.1 Publication
Manual assertion based on experiment ini
- Ref.54"Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes."
Barber L.D., Gillece-Castro B., Percival L., Li X., Clayberger C., Parham P.
Curr. Biol. 5:179-190(1995) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*07:02; B*54:01; B*55:01; B*56:01 AND B*67:01).
Allele B*56:01: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Ala anchor residue at the C-terminus.1 Publication
Manual assertion based on experiment ini
- Ref.54"Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes."
Barber L.D., Gillece-Castro B., Percival L., Li X., Clayberger C., Parham P.
Curr. Biol. 5:179-190(1995) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*07:02; B*54:01; B*55:01; B*56:01 AND B*67:01).
Allele B*57:01: The peptide-bound form recognizes KIR3DL1 and inhibits NK cell cytotoxic response.2 Publications
Manual assertion based on experiment ini
- Ref.72"The interaction of KIR3DL1*001 with HLA class I molecules is dependent upon molecular microarchitecture within the Bw4 epitope."
Saunders P.M., Vivian J.P., Baschuk N., Beddoe T., Widjaja J., O'Connor G.M., Hitchen C., Pymm P., Andrews D.M., Gras S., McVicar D.W., Rossjohn J., Brooks A.G.
J. Immunol. 194:781-789(2015) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*08:01 AND B*57:01), DOMAIN, BW4 AND BW6 MOTIFS, INTERACTION WITH KIR3DL1, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS ILE-104 AND ARG-107. - Ref.79"Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B."
Vivian J.P., Duncan R.C., Berry R., O'Connor G.M., Reid H.H., Beddoe T., Gras S., Saunders P.M., Olshina M.A., Widjaja J.M., Harpur C.M., Lin J., Maloveste S.M., Price D.A., Lafont B.A., McVicar D.W., Clements C.S., Brooks A.G., Rossjohn J.
Nature 479:401-405(2011) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 25-299 (ALLELE B*57:01) IN COMPLEX WITH B2M AND SELF-PEPTIDE, INTERACTION WITH KIR3DL1, DOMAIN, BW4 MOTIF, FUNCTION (ALLELE B*57:01).
Allele B*67:01: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Leu anchor residue at the C-terminus.1 Publication
Manual assertion based on experiment ini
- Ref.54"Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes."
Barber L.D., Gillece-Castro B., Percival L., Li X., Clayberger C., Parham P.
Curr. Biol. 5:179-190(1995) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*07:02; B*54:01; B*55:01; B*56:01 AND B*67:01).
Sites
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the <a href="http://www.uniprot.org/help/function%5Fsection">Function</a> section describes the interaction between a single amino acid and another chemical entity. Priority is given to the annotation of physiological ligands.<p><a href='/help/binding' target='_top'>More...</a></p>Binding sitei | 87 | Peptide antigen; pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 108 | Peptide antigen; pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 167 | Peptide antigen; pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 170 | Peptide antigen; pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 176 | Peptide antigen; pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 183 | Peptide antigen; pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 195 | Peptide antigen; pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 |
<p>The <a href="http://www.geneontology.org/">Gene Ontology (GO)</a> project provides a set of hierarchical controlled vocabulary split into 3 categories:<p><a href='/help/gene_ontology' target='_top'>More...</a></p>GO - Molecular functioni
- chaperone binding Source: UniProtKB
<p>Inferred from Physical Interaction</p>
<p>Covers physical interactions between the gene product of interest and another molecule (or ion, or complex).</p>
<p>More information in the <a href="http://geneontology.org/page/guide%2Dgo%2Devidence%2Dcodes#ipi">GO evidence code guide</a></p>
Inferred from physical interactioni
- "Major histocompatibility complex class I molecules expressed with monoglucosylated N-linked glycans bind calreticulin independently of their assembly status."
Wearsch P.A., Jakob C.A., Vallin A., Dwek R.A., Rudd P.M., Cresswell P.
J Biol Chem 279:25112-25121(2004) [PubMed] [Europe PMC] [Abstract]
- peptide antigen binding Source: UniProtKB
<p>Inferred from Direct Assay</p>
<p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p>
<p>More information in the <a href="http://geneontology.org/page/guide%2Dgo%2Devidence%2Dcodes#ida">GO evidence code guide</a></p>
Inferred from direct assayi
- "Multiple viral ligands naturally presented by different class I molecules in transporter antigen processing-deficient vaccinia virus-infected cells."
Lorente E., Infantes S., Barnea E., Beer I., Garcia R., Lasala F., Jimenez M., Vilches C., Lemonnier F.A., Admon A., Lopez D.
J Virol 86:527-541(2012) [PubMed] [Europe PMC] [Abstract]
- signaling receptor binding Source: UniProtKBInferred from physical interactioni
- "Human natural killer cell receptors for HLA-class I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B alleles."
Moretta A., Vitale M., Sivori S., Bottino C., Morelli L., Augugliaro R., Barbaresi M., Pende D., Ciccone E., Lopez-Botet M., Moretta L.
J Exp Med 180:545-555(1994) [PubMed] [Europe PMC] [Abstract]
- TAP binding Source: UniProtKBInferred from direct assayi
- "Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing."
Neisig A., Wubbolts R., Zang X., Melief C., Neefjes J.
J Immunol 156:3196-3206(1996) [PubMed] [Europe PMC] [Abstract]
GO - Biological processi
- adaptive immune response Source: UniProtKB-KW
- antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent Source: UniProtKBInferred from direct assayi
- "Multiple viral ligands naturally presented by different class I molecules in transporter antigen processing-deficient vaccinia virus-infected cells."
Lorente E., Infantes S., Barnea E., Beer I., Garcia R., Lasala F., Jimenez M., Vilches C., Lemonnier F.A., Admon A., Lopez D.
J Virol 86:527-541(2012) [PubMed] [Europe PMC] [Abstract]
- antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent Source: Reactome
- antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent Source: Reactome
- antigen processing and presentation of peptide antigen via MHC class I Source: Reactome
- defense response Source: UniProtKB
<p>Traceable Author Statement</p>
<p>Used for information from review articles where the original experiments are traceable through that article and also for information from text books or dictionaries.</p>
<p>More information in the <a href="http://geneontology.org/page/guide%2Dgo%2Devidence%2Dcodes#tas">GO evidence code guide</a></p>
Traceable author statementi
- Ref.23"Gene conversion-like mechanisms may generate polymorphism in human class I genes."
Seemann G.H.A., Rein R.S., Brown C.S., Ploegh H.L.
EMBO J. 5:547-552(1986) [PubMed] [Europe PMC] [Abstract]Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*27:05).
- detection of bacterium Source: UniProtKB
<p>Inferred from Mutant Phenotype</p>
<p>Describes annotations that are concluded from looking at variations or changes in a gene product such as mutations or abnormal levels and includes techniques such as knockouts, overexpression, anti-sense experiments and use of specific protein inhibitors.</p>
<p>More information in the <a href="http://geneontology.org/page/guide%2Dgo%2Devidence%2Dcodes#imp">GO evidence code guide</a></p>
Inferred from mutant phenotypei
- "HLA molecules and nasal carriage of Staphylococcus aureus isolated from dialysis and kidney transplant patients at a hospital in Southern Brazil."
Giarola L.B., Dos Santos R.R., Bedendo J., da Silva Junior W.V., Borelli S.D.
BMC Res Notes 5:90-90(2012) [PubMed] [Europe PMC] [Abstract]
- immune response Source: UniProtKBInferred from mutant phenotypei
- "HLA molecules and nasal carriage of Staphylococcus aureus isolated from dialysis and kidney transplant patients at a hospital in Southern Brazil."
Giarola L.B., Dos Santos R.R., Bedendo J., da Silva Junior W.V., Borelli S.D.
BMC Res Notes 5:90-90(2012) [PubMed] [Europe PMC] [Abstract]
- interferon-gamma-mediated signaling pathway Source: Reactome
- neutrophil degranulation Source: Reactome
- positive regulation of T cell mediated cytotoxicity Source: UniProtKBInferred from direct assayi
- "The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides."
Townsend A.R., Rothbard J., Gotch F.M., Bahadur G., Wraith D., McMichael A.J.
Cell 44:959-968(1986) [PubMed] [Europe PMC] [Abstract]
- protection from natural killer cell mediated cytotoxicity Source: UniProtKBInferred from direct assayi
- "Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1."
Stern M., Ruggeri L., Capanni M., Mancusi A., Velardi A.
Blood 112:708-710(2008) [PubMed] [Europe PMC] [Abstract] - "Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes."
Storkus W.J., Alexander J., Payne J.A., Dawson J.R., Cresswell P.
Proc Natl Acad Sci U S A 86:2361-2364(1989) [PubMed] [Europe PMC] [Abstract] - "Human natural killer cell receptors for HLA-class I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B alleles."
Moretta A., Vitale M., Sivori S., Bottino C., Morelli L., Augugliaro R., Barbaresi M., Pende D., Ciccone E., Lopez-Botet M., Moretta L.
J Exp Med 180:545-555(1994) [PubMed] [Europe PMC] [Abstract]
- regulation of dendritic cell differentiation Source: BHF-UCLInferred from mutant phenotypei
- "HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses."
Huang J., Goedert J.J., Sundberg E.J., Cung T.D., Burke P.S., Martin M.P., Preiss L., Lifson J., Lichterfeld M., Carrington M., Yu X.G.
J Exp Med 206:2959-2966(2009) [PubMed] [Europe PMC] [Abstract]
- regulation of immune response Source: Reactome
- regulation of interleukin-12 production Source: BHF-UCLInferred from mutant phenotypei
- "HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses."
Huang J., Goedert J.J., Sundberg E.J., Cung T.D., Burke P.S., Martin M.P., Preiss L., Lifson J., Lichterfeld M., Carrington M., Yu X.G.
J Exp Med 206:2959-2966(2009) [PubMed] [Europe PMC] [Abstract]
- regulation of interleukin-6 production Source: BHF-UCLInferred from mutant phenotypei
- "HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses."
Huang J., Goedert J.J., Sundberg E.J., Cung T.D., Burke P.S., Martin M.P., Preiss L., Lifson J., Lichterfeld M., Carrington M., Yu X.G.
J Exp Med 206:2959-2966(2009) [PubMed] [Europe PMC] [Abstract]
- regulation of T cell anergy Source: BHF-UCLInferred from mutant phenotypei
- "HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses."
Huang J., Goedert J.J., Sundberg E.J., Cung T.D., Burke P.S., Martin M.P., Preiss L., Lifson J., Lichterfeld M., Carrington M., Yu X.G.
J Exp Med 206:2959-2966(2009) [PubMed] [Europe PMC] [Abstract]
- type I interferon signaling pathway Source: Reactome
- viral process Source: UniProtKB-KW
<p>UniProtKB Keywords constitute a <a href="http://www.uniprot.org/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywordsi
| Biological process | Adaptive immunity, Host-virus interaction, Immunity, Innate immunity |
Enzyme and pathway databases
Pathway Commons web resource for biological pathway data More...PathwayCommonsi | P01889 |
Reactome - a knowledgebase of biological pathways and processes More...Reactomei | R-HSA-1236974, ER-Phagosome pathway R-HSA-1236977, Endosomal/Vacuolar pathway R-HSA-198933, Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell R-HSA-2172127, DAP12 interactions R-HSA-6798695, Neutrophil degranulation R-HSA-877300, Interferon gamma signaling R-HSA-909733, Interferon alpha/beta signaling R-HSA-983170, Antigen Presentation: Folding, assembly and peptide loading of class I MHC |
SIGNOR Signaling Network Open Resource More...SIGNORi | P01889 |
<p>This section provides information about the protein and gene name(s) and synonym(s) and about the organism that is the source of the protein sequence.<p><a href='/help/names_and_taxonomy_section' target='_top'>More...</a></p>Names & Taxonomyi
| <p>This subsection of the <a href="http://www.uniprot.org/help/names%5Fand%5Ftaxonomy%5Fsection">Names and taxonomy</a> section provides an exhaustive list of all names of the protein, from commonly used to obsolete, to allow unambiguous identification of a protein.<p><a href='/help/protein_names' target='_top'>More...</a></p>Protein namesi | Recommended name: HLA class I histocompatibility antigen, B alpha chainAlternative name(s): Human leukocyte antigen B Short name: HLA-B |
| <p>This subsection of the <a href="http://www.uniprot.org/help/names%5Fand%5Ftaxonomy%5Fsection">Names and taxonomy</a> section indicates the name(s) of the gene(s) that code for the protein sequence(s) described in the entry. Four distinct tokens exist: 'Name', 'Synonyms', 'Ordered locus names' and 'ORF names'.<p><a href='/help/gene_name' target='_top'>More...</a></p>Gene namesi | |
| <p>This subsection of the <a href="http://www.uniprot.org/help/names%5Fand%5Ftaxonomy%5Fsection">Names and taxonomy</a> section provides information on the name(s) of the organism that is the source of the protein sequence.<p><a href='/help/organism-name' target='_top'>More...</a></p>Organismi | Homo sapiens (Human) |
| <p>This subsection of the <a href="http://www.uniprot.org/help/names%5Fand%5Ftaxonomy%5Fsection">Names and taxonomy</a> section shows the unique identifier assigned by the NCBI to the source organism of the protein. This is known as the 'taxonomic identifier' or 'taxid'.<p><a href='/help/taxonomic_identifier' target='_top'>More...</a></p>Taxonomic identifieri | 9606 [NCBI] |
| <p>This subsection of the <a href="http://www.uniprot.org/help/names%5Fand%5Ftaxonomy%5Fsection">Names and taxonomy</a> section contains the taxonomic hierarchical classification lineage of the source organism. It lists the nodes as they appear top-down in the taxonomic tree, with the more general grouping listed first.<p><a href='/help/taxonomic_lineage' target='_top'>More...</a></p>Taxonomic lineagei | cellular organisms › Eukaryota › Opisthokonta › Metazoa › Eumetazoa › Bilateria › Deuterostomia › Chordata › Craniata › Vertebrata › Gnathostomata › Teleostomi › Euteleostomi › Sarcopterygii › Dipnotetrapodomorpha › Tetrapoda › Amniota › Mammalia › Theria › Eutheria › Boreoeutheria › Euarchontoglires › Primates › Haplorrhini › Simiiformes › Catarrhini › Hominoidea › Hominidae › Homininae › Homo |
| <p>This subsection of the <a href="http://www.uniprot.org/help/names%5Fand%5Ftaxonomy%5Fsection">Names and taxonomy</a> section is present for entries that are part of a <a href="http://www.uniprot.org/proteomes">proteome</a>, i.e. of a set of proteins thought to be expressed by organisms whose genomes have been completely sequenced.<p><a href='/help/proteomes_manual' target='_top'>More...</a></p>Proteomesi |
|
Organism-specific databases
Human Gene Nomenclature Database More...HGNCi | HGNC:4932, HLA-B |
neXtProt; the human protein knowledge platform More...neXtProti | NX_P01889 |
Eukaryotic Pathogen, Vector and Host Database Resources More...VEuPathDBi | HostDB:ENSG00000234745.9 |
<p>This section provides information on the location and the topology of the mature protein in the cell.<p><a href='/help/subcellular_location_section' target='_top'>More...</a></p>Subcellular locationi
Plasma membrane
- Cell membrane 3 Publications
Manual assertion based on experiment ini
- Ref.57"HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading."
Peh C.A., Burrows S.R., Barnden M., Khanna R., Cresswell P., Moss D.J., McCluskey J.
Immunity 8:531-542(1998) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*08:01; B*27:05 AND B*44:02), INTERACTION WITH TAP1-TAP2, SUBCELLULAR LOCATION. - Ref.71"TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst."
Hermann C., van Hateren A., Trautwein N., Neerincx A., Duriez P.J., Stevanovic S., Trowsdale J., Deane J.E., Elliott T., Boyle L.H.
Elife 4:0-0(2015) [PubMed] [Europe PMC] [Abstract]Cited for: INTERACTION WITH TAPBPL, SUBCELLULAR LOCATION. - Ref.72"The interaction of KIR3DL1*001 with HLA class I molecules is dependent upon molecular microarchitecture within the Bw4 epitope."
Saunders P.M., Vivian J.P., Baschuk N., Beddoe T., Widjaja J., O'Connor G.M., Hitchen C., Pymm P., Andrews D.M., Gras S., McVicar D.W., Rossjohn J., Brooks A.G.
J. Immunol. 194:781-789(2015) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*08:01 AND B*57:01), DOMAIN, BW4 AND BW6 MOTIFS, INTERACTION WITH KIR3DL1, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS ILE-104 AND ARG-107.
- Cell membrane 3 Publications
Endoplasmic reticulum
- Endoplasmic reticulum membrane 1 Publication
<p>Manually curated information which has been inferred by a curator based on his/her scientific knowledge or on the scientific content of an article.</p> <p><a href="/manual/evidences#ECO:0000305">More...</a></p> Manual assertion inferred by curator fromi
- Ref.57"HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading."
Peh C.A., Burrows S.R., Barnden M., Khanna R., Cresswell P., Moss D.J., McCluskey J.
Immunity 8:531-542(1998) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*08:01; B*27:05 AND B*44:02), INTERACTION WITH TAP1-TAP2, SUBCELLULAR LOCATION.
- Endoplasmic reticulum membrane 1 Publication
Endoplasmic reticulum
- endoplasmic reticulum Source: UniProtKBInferred from direct assayi
- "Receptor-mediated ER export of human MHC class I molecules is regulated by the C-terminal single amino acid."
Cho S., Ryoo J., Jun Y., Ahn K.
Traffic 12:42-55(2011) [PubMed] [Europe PMC] [Abstract]
- integral component of lumenal side of endoplasmic reticulum membrane Source: Reactome
- endoplasmic reticulum Source: UniProtKBInferred from direct assayi
Endosome
- early endosome membrane Source: Reactome
- recycling endosome membrane Source: Reactome
Extracellular region or secreted
- extracellular exosome Source: UniProtKBInferred from high throughput direct assayi
- "Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation."
Wubbolts R., Leckie R.S., Veenhuizen P.T., Schwarzmann G., Mobius W., Hoernschemeyer J., Slot J.W., Geuze H.J., Stoorvogel W.
J Biol Chem 278:10963-10972(2003) [PubMed] [Europe PMC] [Abstract] - "Large-scale proteomics and phosphoproteomics of urinary exosomes."
Gonzales P.A., Pisitkun T., Hoffert J.D., Tchapyjnikov D., Star R.A., Kleta R., Wang N.S., Knepper M.A.
J Am Soc Nephrol 20:363-379(2009) [PubMed] [Europe PMC] [Abstract] - "Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT)."
Gonzalez-Begne M., Lu B., Han X., Hagen F.K., Hand A.R., Melvin J.E., Yates J.R.
J Proteome Res 8:1304-1314(2009) [PubMed] [Europe PMC] [Abstract] - "MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis."
Buschow S.I., van Balkom B.W., Aalberts M., Heck A.J., Wauben M., Stoorvogel W.
Immunol Cell Biol 88:851-856(2010) [PubMed] [Europe PMC] [Abstract]
- extracellular exosome Source: UniProtKBInferred from high throughput direct assayi
Golgi apparatus
- Golgi apparatus Source: UniProtKBInferred from direct assayi
- "Receptor-mediated ER export of human MHC class I molecules is regulated by the C-terminal single amino acid."
Cho S., Ryoo J., Jun Y., Ahn K.
Traffic 12:42-55(2011) [PubMed] [Europe PMC] [Abstract]
- Golgi membrane Source: Reactome
- Golgi apparatus Source: UniProtKBInferred from direct assayi
Plasma Membrane
- integral component of plasma membrane Source: UniProtKB
<p>Non-traceable Author Statement</p>
<p>Used for statements in the abstract, introduction or discussion of a paper that cannot be traced back to another publication.</p>
<p>More information in the <a href="http://geneontology.org/page/guide%2Dgo%2Devidence%2Dcodes#nas">GO evidence code guide</a></p>
Non-traceable author statementi
- Ref.28"Diversity and diversification of HLA-A,B,C alleles."
Parham P., Lawlor D.A., Lomen C.E., Ennis P.D.
J. Immunol. 142:3937-3950(1989) [PubMed] [Europe PMC] [Abstract]Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*08:01; B*13:02; B*14:01; B*18:01; B*41:01; B*42:01; B*44:02 AND B*46:01). - Ref.52"Complete amino acid sequence of a papain-solubilized human histocompatibility antigen, HLA-B7. 2. Sequence determination and search for homologies."
Orr H.T., Lopez de Castro J.A., Lancet D., Strominger J.L.
Biochemistry 18:5711-5720(1979) [PubMed] [Europe PMC] [Abstract]Cited for: PROTEIN SEQUENCE OF 25-295 (B*07:02). - Ref.32"Molecular analysis of HLA-B39 subtypes."
Kato N., Karaki S., Kashiwase K., Mueller C., Akaza T., Juji T., Kano K., Takiguchi M.
Immunogenetics 37:212-216(1993) [PubMed] [Europe PMC] [Abstract]Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*39:02). - "Antagonist HIV-1 Gag peptides induce structural changes in HLA B8."
Reid S.W., McAdam S., Smith K.J., Klenerman P., O'Callaghan C.A., Harlos K., Jakobsen B.K., McMichael A.J., Bell J.I., Stuart D.I., Jones E.Y.
J Exp Med 184:2279-2286(1996) [PubMed] [Europe PMC] [Abstract]
- MHC class I protein complex Source: UniProtKBInferred from direct assayi
- "Multiple viral ligands naturally presented by different class I molecules in transporter antigen processing-deficient vaccinia virus-infected cells."
Lorente E., Infantes S., Barnea E., Beer I., Garcia R., Lasala F., Jimenez M., Vilches C., Lemonnier F.A., Admon A., Lopez D.
J Virol 86:527-541(2012) [PubMed] [Europe PMC] [Abstract]
- plasma membrane Source: Reactome
- integral component of plasma membrane Source: UniProtKB
<p>Non-traceable Author Statement</p>
<p>Used for statements in the abstract, introduction or discussion of a paper that cannot be traced back to another publication.</p>
<p>More information in the <a href="http://geneontology.org/page/guide%2Dgo%2Devidence%2Dcodes#nas">GO evidence code guide</a></p>
Non-traceable author statementi
Other locations
- cell surface Source: UniProtKBInferred from direct assayi
- "Multiple viral ligands naturally presented by different class I molecules in transporter antigen processing-deficient vaccinia virus-infected cells."
Lorente E., Infantes S., Barnea E., Beer I., Garcia R., Lasala F., Jimenez M., Vilches C., Lemonnier F.A., Admon A., Lopez D.
J Virol 86:527-541(2012) [PubMed] [Europe PMC] [Abstract] - "HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer."
Llano M., Lee N., Navarro F., Garcia P., Albar J.P., Geraghty D.E., Lopez-Botet M.
Eur. J. Immunol. 28:2854-2863(1998) [PubMed] [Europe PMC] [Abstract]
- ER to Golgi transport vesicle membrane Source: Reactome
- membrane Source: UniProtKBInferred from high throughput direct assayi
- "Defining the membrane proteome of NK cells."
Ghosh D., Lippert D., Krokhin O., Cortens J.P., Wilkins J.A.
J Mass Spectrom 45:1-25(2010) [PubMed] [Europe PMC] [Abstract]
- phagocytic vesicle membrane Source: Reactome
- secretory granule membrane Source: Reactome
- cell surface Source: UniProtKBInferred from direct assayi
Topology
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the <a href="http://www.uniprot.org/help/subcellular%5Flocation%5Fsection">'Subcellular location'</a> section describes the subcellular compartment where each non-membrane region of a membrane-spanning protein is found.<p><a href='/help/topo_dom' target='_top'>More...</a></p>Topological domaini | 25 – 309 | ExtracellularSequence analysisAdd BLAST | 285 | |
| <p>This subsection of the <a href="http://www.uniprot.org/help/subcellular%5Flocation%5Fsection">'Subcellular location'</a> section describes the extent of a membrane-spanning region of the protein. It denotes the presence of both alpha-helical transmembrane regions and the membrane spanning regions of beta-barrel transmembrane proteins.<p><a href='/help/transmem' target='_top'>More...</a></p>Transmembranei | 310 – 333 | HelicalSequence analysisAdd BLAST | 24 | |
| Topological domaini | 334 – 362 | CytoplasmicSequence analysisAdd BLAST | 29 |
Keywords - Cellular componenti
Cell membrane, Endoplasmic reticulum, Membrane, MHC I<p>This section provides information on the disease(s) and phenotype(s) associated with a protein.<p><a href='/help/pathology_and_biotech_section' target='_top'>More...</a></p>Pathology & Biotechi
<p>This subsection of the 'Pathology and Biotech' section provides information on the disease(s) associated with genetic variations in a given protein. The information is extracted from the scientific literature and diseases that are also described in the <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim">OMIM</a> database are represented with a <a href="http://www.uniprot.org/diseases">controlled vocabulary</a> in the following way:<p><a href='/help/involvement_in_disease' target='_top'>More...</a></p>Involvement in diseasei
Stevens-Johnson syndrome (SJS)
Disease susceptibility is associated with variants affecting the gene represented in this entry. Increased susceptibility to Stevens-Johnson syndrome is conferred by allele B*15:02.1 Publication
Manual assertion based on experiment ini
- Ref.85"Medical genetics: a marker for Stevens-Johnson syndrome."
Chung W.-H., Hung S.-I., Hong H.-S., Hsih M.-S., Yang L.-C., Ho H.-C., Wu J.-Y., Chen Y.-T.
Nature 428:486-486(2004) [PubMed] [Europe PMC] [Abstract]Cited for: ASSOCIATION OF ALLELE B*15:02 WITH STEVENS-JOHNSON SYNDROME.
Disease descriptionA rare blistering mucocutaneous disease that share clinical and histopathologic features with toxic epidermal necrolysis. Both disorders are characterized by high fever, malaise, and a rapidly developing blistering exanthema of macules and target-like lesions accompanied by mucosal involvement. Stevens-Johnson syndrome is a milder disease characterized by destruction and detachment of the skin epithelium and mucous membranes involving less than 10% of the body surface area. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis and sometimes blindness. It can be caused by a severe adverse reaction to particular types of medication, although Mycoplasma infections may induce some cases.
Related information in OMIMSpondyloarthropathy 1 (SPDA1)
Disease susceptibility is associated with variants affecting the gene represented in this entry. A restricted number of HLA-B*27 subtypes can be associated with ankylosing spondylitis and other B*27-related diseases, and an elevated frequency of the B*27:02 allele in ankylosing spondylitis patients is identified. The allele B*27:07 seems to have a protective role in some populations because it was found only in the healthy controls.1 Publication
Manual assertion based on experiment ini
- Ref.84"HLA-B27 in the Greek Cypriot population: distribution of subtypes in patients with ankylosing spondylitis and other HLA-B27-related diseases. The possible protective role of B*2707."
Varnavidou-Nicolaidou A., Karpasitou K., Georgiou D., Stylianou G., Kokkofitou A., Michalis C., Constantina C., Gregoriadou C., Kyriakides G.
Hum. Immunol. 65:1451-1454(2004) [PubMed] [Europe PMC] [Abstract]Cited for: ASSOCIATION WITH SPDA1, POSSIBLE PROTECTIVE ROLE OF ALLELE B*27:07.
Disease descriptionA chronic rheumatic disease with multifactorial inheritance. It includes a spectrum of related disorders comprising ankylosing spondylitis, a subset of psoriatic arthritis, reactive arthritis (e.g. Reiter syndrome), arthritis associated with inflammatory bowel disease and undifferentiated spondyloarthropathy. These disorders may occur simultaneously or sequentially in the same patient, probably representing various phenotypic expressions of the same disease. Ankylosing spondylitis is the form of rheumatoid arthritis affecting the spine and is considered the prototype of seronegative spondyloarthropathies. It produces pain and stiffness as a result of inflammation of the sacroiliac, intervertebral, and costovertebral joints.
Related information in OMIMThere is evidence that HLA-B*51 is associated with susceptibility to Behcet disease (BD). However, it is not certain whether HLA-B*51 itself or a closely linked gene is responsible for susceptibility. The world distribution of HLA-B*51 in healthy people corresponds to the global distribution of BD; in Southern hemisphere countries (Africa, South Pacific, etc.) and in some parts of Europe, the prevalence of HLA-B*51 in healthy people is low or null, corresponding to a low prevalence of BD. The wide variation that exists in the relative risk of HLA-B*51 would support other nongenetic risk factors.1 Publication
Manual assertion based on experiment ini
- Ref.87"Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B*51 and ERAP1."
Kirino Y., Bertsias G., Ishigatsubo Y., Mizuki N., Tugal-Tutkun I., Seyahi E., Ozyazgan Y., Sacli F.S., Erer B., Inoko H., Emrence Z., Cakar A., Abaci N., Ustek D., Satorius C., Ueda A., Takeno M., Kim Y. , Wood G.M., Ombrello M.J., Meguro A., Guel A., Remmers E.F., Kastner D.L.
Nat. Genet. 45:202-207(2013) [PubMed] [Europe PMC] [Abstract]Cited for: ASSOCIATION OF ALLELE GROUP B*51 WITH BEHCET DISEASE.
The presence of allele B*57:01 is associated with increased susceptibility to abacavir hypersensitivity [MIM:142830] in HIV-1 patients.1 Publication
Manual assertion based on experiment ini
- Ref.83"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir."
Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C., Sayer D., Castley A., Mamotte C., Maxwell D., James I., Christiansen F.T.
Lancet 359:727-732(2002) [PubMed] [Europe PMC] [Abstract]Cited for: ASSOCIATION WITH ABACAVIR HYPERSENSITIVITY.
Allele group B*08 is associated with increased susceptibility to rheumatoid arthritis, where affected individuals have antibodies to cyclic citrullinated peptide (anti-CCP-positive rheumatoid arthritis).1 Publication
Manual assertion based on experiment ini
- Ref.86"Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis."
Raychaudhuri S., Sandor C., Stahl E.A., Freudenberg J., Lee H.S., Jia X., Alfredsson L., Padyukov L., Klareskog L., Worthington J., Siminovitch K.A., Bae S.C., Plenge R.M., Gregersen P.K., de Bakker P.I.
Nat. Genet. 44:291-296(2012) [PubMed] [Europe PMC] [Abstract]Cited for: INVOLVEMENT IN RA, ASSOCIATION OF ALLELE GROUP B*8 WITH RHEUMATOID ARTHRITIS, VARIANT ASP-33.
Organism-specific databases
DisGeNET More...DisGeNETi | 3106 |
MalaCards human disease database More...MalaCardsi | HLA-B |
Online Mendelian Inheritance in Man (OMIM) More...MIMi | 106300, phenotype 608579, phenotype |
Open Targets More...OpenTargetsi | ENSG00000234745 |
Orphanet; a database dedicated to information on rare diseases and orphan drugs More...Orphaneti | 240841, Abacavir toxicity 240845, Allopurinol toxicity 117, Behcet disease 240871, Flucloxacilline toxicity 825, NON RARE IN EUROPE: Ankylosing spondylitis 414750, Phenytoin or carbamazepine toxicity 275798, Pulmonary arterial hypertension associated with connective tissue disease 36426, Stevens-Johnson syndrome 3287, Takayasu arteritis |
The Pharmacogenetics and Pharmacogenomics Knowledge Base More...PharmGKBi | PA35056 |
Miscellaneous databases
Pharos NIH Druggable Genome Knowledgebase More...Pharosi | P01889, Tbio |
Chemistry databases
Drug and drug target database More...DrugBanki | DB01048, Abacavir DB11294, Coccidioides immitis spherule DB04464, N-Formylmethionine |
<p>This section describes post-translational modifications (PTMs) and/or processing events.<p><a href='/help/ptm_processing_section' target='_top'>More...</a></p>PTM / Processingi
Molecule processing
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the 'PTM / Processing' section denotes the presence of an N-terminal signal peptide.<p><a href='/help/signal' target='_top'>More...</a></p>Signal peptidei | 1 – 24 | 1 Publication Manual assertion based on experiment ini
| 24 | |
| <p>This subsection of the 'PTM / Processing' section describes the extent of a polypeptide chain in the mature protein following processing or proteolytic cleavage.<p><a href='/help/chain' target='_top'>More...</a></p>ChainiPRO_0000018833 | 25 – 362 | HLA class I histocompatibility antigen, B alpha chainAdd BLAST | 338 |
Amino acid modifications
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the <a href="http://www.uniprot.org/help/ptm%5Fprocessing%5Fsection">PTM / Processing</a> section specifies the position and type of each covalently attached glycan group (mono-, di-, or polysaccharide).<p><a href='/help/carbohyd' target='_top'>More...</a></p>Glycosylationi | 110 | N-linked (GlcNAc...) asparagine1 Publication Manual assertion based on experiment ini
| 1 | |
| <p>This subsection of the PTM / Processing":/help/ptm_processing_section section describes the positions of cysteine residues participating in disulfide bonds.<p><a href='/help/disulfid' target='_top'>More...</a></p>Disulfide bondi | 125 ↔ 188 | PROSITE-ProRule annotation <p>Manual validated information which has been generated by the UniProtKB automatic annotation system.</p> <p><a href="/manual/evidences#ECO:0000255">More...</a></p> Manual assertion according to rulesi 3 PublicationsManual assertion based on experiment ini
| ||
| Disulfide bondi | 227 ↔ 283 | PROSITE-ProRule annotation Manual assertion according to rulesi 3 PublicationsManual assertion based on experiment ini
|
Keywords - PTMi
Disulfide bond, Glycoprotein, PhosphoproteinProteomic databases
Encyclopedia of Proteome Dynamics More...EPDi | P01889 |
jPOST - Japan Proteome Standard Repository/Database More...jPOSTi | P01889 |
MassIVE - Mass Spectrometry Interactive Virtual Environment More...MassIVEi | P01889 |
MaxQB - The MaxQuant DataBase More...MaxQBi | P01889 |
PaxDb, a database of protein abundance averages across all three domains of life More...PaxDbi | P01889 |
PeptideAtlas More...PeptideAtlasi | P01889 |
PRoteomics IDEntifications database More...PRIDEi | P01889 |
ProteomicsDB: a multi-organism proteome resource More...ProteomicsDBi | 51504 51628 52598 53565 53566 53567 54677 54678 54679 54680 54681 54682 54683 54684 54685 54686 54687 54688 54689 54690 54691 54692 54693 54694 54695 54696 54697 54732 58284 61272 61273 61276 61584 61586 75730 |
PTM databases
GlyConnect protein glycosylation platform More...GlyConnecti | 1331, 1 N-Linked glycan (1 site) 1332, 8 N-Linked glycans (1 site) 1333, 8 N-Linked glycans (1 site) 1334, 5 N-Linked glycans (1 site) 1335, 2 N-Linked glycans (1 site) 1336, 2 N-Linked glycans (1 site) 1337, 8 N-Linked glycans (1 site) 1338, 2 N-Linked glycans (1 site) 1339, 2 N-Linked glycans (1 site) 1340, 3 N-Linked glycans (1 site) 1341, 8 N-Linked glycans (1 site) 1342, 2 N-Linked glycans (1 site) 1343, 2 N-Linked glycans (1 site) 1344, 3 N-Linked glycans (1 site) 1345, 1 N-Linked glycan (1 site) 1346, 3 N-Linked glycans (1 site) 1347, 8 N-Linked glycans (1 site) 1348, 2 N-Linked glycans (1 site) 1349, 2 N-Linked glycans (1 site) 1350, 8 N-Linked glycans (1 site) 1351, 2 N-Linked glycans (1 site) |
GlyGen: Computational and Informatics Resources for Glycoscience More...GlyGeni | P01889, 2 sites, 1 O-linked glycan (1 site) |
iPTMnet integrated resource for PTMs in systems biology context More...iPTMneti | P01889 |
Comprehensive resource for the study of protein post-translational modifications (PTMs) in human, mouse and rat. More...PhosphoSitePlusi | P01889 |
SwissPalm database of S-palmitoylation events More...SwissPalmi | P01889 |
<p>This section provides information on the expression of a gene at the mRNA or protein level in cells or in tissues of multicellular organisms.<p><a href='/help/expression_section' target='_top'>More...</a></p>Expressioni
Gene expression databases
Bgee dataBase for Gene Expression Evolution More...Bgeei | ENSG00000234745, Expressed in testis and 117 other tissues |
ExpressionAtlas, Differential and Baseline Expression More...ExpressionAtlasi | P01889, baseline and differential |
Organism-specific databases
Human Protein Atlas More...HPAi | ENSG00000234745, Low tissue specificity |
<p>This section provides information on the quaternary structure of a protein and on interaction(s) with other proteins or protein complexes.<p><a href='/help/interaction_section' target='_top'>More...</a></p>Interactioni
<p>This subsection of the <a href="http://www.uniprot.org/help/interaction%5Fsection">'Interaction'</a> section provides information about the protein quaternary structure and interaction(s) with other proteins or protein complexes (with the exception of physiological receptor-ligand interactions which are annotated in the <a href="http://www.uniprot.org/help/function%5Fsection">'Function'</a> section).<p><a href='/help/subunit_structure' target='_top'>More...</a></p>Subunit structurei
Heterotrimer that consists of an alpha chain HLA-B, a beta chain B2M and a peptide (peptide-HLA-B-B2M) (PubMed:25808313, PubMed:29531227, PubMed:15657948, PubMed:17057332, PubMed:22020283, PubMed:24600035). Early in biogenesis, HLA-B-B2M dimer interacts with the components of the peptide-loading complex composed of TAPBP, TAP1-TAP2, TAPBPL, PDIA3/ERP57 and CALR (PubMed:9036970, PubMed:9620674, PubMed:26439010, PubMed:26416272).
Interacts with TAP1-TAP2 transporter via TAPBP; this interaction is obligatory for the loading of peptide epitopes delivered to the ER by TAP1-TAP2 transporter (PubMed:9036970, PubMed:9620674).
Interacts with TAPBPL; TAPBPL binds peptide-free HLA-B-B2M complexes or those loaded with low affinity peptides, likely facilitating peptide exchange for higher affinity peptides (PubMed:26439010). Only optimally assembled peptide-HLA-B-B2M trimer translocates to the surface of antigen-presenting cells, where it interacts with TCR and CD8 coreceptor on the surface of T cells. HLA-B (via polymorphic alpha-1 and alpha-2 domains) interacts with antigen-specific TCR (via CDR1, CDR2 and CDR3 domains) (PubMed:29531227, PubMed:24600035). One HLA-B molecule (mainly via nonpolymorphic alpha-3 domain) interacts with one CD8A homodimer (via CDR-like loop); this interaction insures peptide-HLA-B-B2M recognition by CD8-positive T cells only (PubMed:29531227). Allele B*57:01 interacts (via Bw4 motif) with KIR3DL1 (via Ig-like C2-type domain); this interaction may interfere with peptide binding (PubMed:22020283, PubMed:25480565). Allele B*46:01 interacts with KIR2DL3 (PubMed:28514659).
12 PublicationsManual assertion based on experiment ini
- Ref.56"Prominence of beta 2-microglobulin, class I heavy chain conformation, and tapasin in the interactions of class I heavy chain with calreticulin and the transporter associated with antigen processing."
Solheim J.C., Harris M.R., Kindle C.S., Hansen T.H.
J. Immunol. 158:2236-2241(1997) [PubMed] [Europe PMC] [Abstract]Cited for: INTERACTION WITH B2M, INTERACTION WITH CALR AND TAP1-TAP2. - Ref.57"HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading."
Peh C.A., Burrows S.R., Barnden M., Khanna R., Cresswell P., Moss D.J., McCluskey J.
Immunity 8:531-542(1998) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*08:01; B*27:05 AND B*44:02), INTERACTION WITH TAP1-TAP2, SUBCELLULAR LOCATION. - Ref.71"TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst."
Hermann C., van Hateren A., Trautwein N., Neerincx A., Duriez P.J., Stevanovic S., Trowsdale J., Deane J.E., Elliott T., Boyle L.H.
Elife 4:0-0(2015) [PubMed] [Europe PMC] [Abstract]Cited for: INTERACTION WITH TAPBPL, SUBCELLULAR LOCATION. - Ref.72"The interaction of KIR3DL1*001 with HLA class I molecules is dependent upon molecular microarchitecture within the Bw4 epitope."
Saunders P.M., Vivian J.P., Baschuk N., Beddoe T., Widjaja J., O'Connor G.M., Hitchen C., Pymm P., Andrews D.M., Gras S., McVicar D.W., Rossjohn J., Brooks A.G.
J. Immunol. 194:781-789(2015) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*08:01 AND B*57:01), DOMAIN, BW4 AND BW6 MOTIFS, INTERACTION WITH KIR3DL1, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS ILE-104 AND ARG-107. - Ref.73"Mechanistic Basis for Epitope Proofreading in the Peptide-Loading Complex."
Fleischmann G., Fisette O., Thomas C., Wieneke R., Tumulka F., Schneeweiss C., Springer S., Schaefer L.V., Tampe R.
J. Immunol. 195:4503-4513(2015) [PubMed] [Europe PMC] [Abstract]Cited for: INTERACTION WITH THE PEPTIDE-LOADING COMPLEX. - Ref.75"The Intergenic Recombinant HLA-B*46:01 Has a Distinctive Peptidome that Includes KIR2DL3 Ligands."
Hilton H.G., McMurtrey C.P., Han A.S., Djaoud Z., Guethlein L.A., Blokhuis J.H., Pugh J.L., Goyos A., Horowitz A., Buchli R., Jackson K.W., Bardet W., Bushnell D.A., Robinson P.J., Mendoza J.L., Birnbaum M.E., Nielsen M., Garcia K.C., Hildebrand W.H., Parham P.
Cell Rep. 19:1394-1405(2017) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE B*46:01), INTERACTION WITH KIR2DL3. - Ref.77"Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705."
Stewart-Jones G.B., di Gleria K., Kollnberger S., McMichael A.J., Jones E.Y., Bowness P.
Eur. J. Immunol. 35:341-351(2005) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-300 (ALLELE B*27:05) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE B*27:05). - Ref.78"Crystal structures of two peptide-HLA-B*1501 complexes; structural characterization of the HLA-B62 supertype."
Roder G., Blicher T., Justesen S., Johannesen B., Kristensen O., Kastrup J., Buus S., Gajhede M.
Acta Crystallogr. D 62:1300-1310(2006) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 25-300 (ALLELE B*15:01) IN COMPLEX WITH EBV NUCLEAR ANTIGEN AND UBE2 PEPTIDES, DISULFIDE BONDS. - Ref.79"Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B."
Vivian J.P., Duncan R.C., Berry R., O'Connor G.M., Reid H.H., Beddoe T., Gras S., Saunders P.M., Olshina M.A., Widjaja J.M., Harpur C.M., Lin J., Maloveste S.M., Price D.A., Lafont B.A., McVicar D.W., Clements C.S., Brooks A.G., Rossjohn J.
Nature 479:401-405(2011) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 25-299 (ALLELE B*57:01) IN COMPLEX WITH B2M AND SELF-PEPTIDE, INTERACTION WITH KIR3DL1, DOMAIN, BW4 MOTIF, FUNCTION (ALLELE B*57:01). - Ref.80"Molecular basis of a dominant T cell response to an HIV reverse transcriptase 8-mer epitope presented by the protective allele HLA-B*51:01."
Motozono C., Kuse N., Sun X., Rizkallah P.J., Fuller A., Oka S., Cole D.K., Sewell A.K., Takiguchi M.
J. Immunol. 192:3428-3434(2014) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.99 ANGSTROMS) OF 25-300 (ALLELE B*51:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE B*51:01). - Ref.81"A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape."
Kloverpris H.N., Cole D.K., Fuller A., Carlson J., Beck K., Schauenburg A.J., Rizkallah P.J., Buus S., Sewell A.K., Goulder P.
Retrovirology 12:20-20(2015) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.59 ANGSTROMS) OF 25-300 (ALLELE B*07:02) IN COMPLEX WITH B2M AND HIV-1 PEPTIDES, DISULFIDE BOND, FUNCTION (ALLELE B*07:02), DOMAIN. - Ref.82"Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide."
Chan K.F., Gully B.S., Gras S., Beringer D.X., Kjer-Nielsen L., Cebon J., McCluskey J., Chen W., Rossjohn J.
Nat. Commun. 9:1026-1026(2018) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) (ALLELE B*07:02) IN COMPLEX WITH B2M AND PEPTIDE, DISULFIDE BOND, INTERACTION WITH TCR, FUNCTION (ALLELE B*07:02).
(Microbial infection) Interacts with HTLV-1 accessory protein p12I.
1 PublicationManual assertion based on experiment ini
- Ref.58"Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein."
Johnson J.M., Nicot C., Fullen J., Ciminale V., Casareto L., Mulloy J.C., Jacobson S., Franchini G.
J. Virol. 75:6086-6094(2001) [PubMed] [Europe PMC] [Abstract]Cited for: INTERACTION WITH HTLV-1 ACCESSORY PROTEIN P12I (MICROBIAL INFECTION).
<p>This subsection of the '<a href="http://www.uniprot.org/help/interaction%5Fsection">Interaction</a>' section provides information about binary protein-protein interactions. The data presented in this section are a quality-filtered subset of binary interactions automatically derived from the <a href="https://www.ebi.ac.uk/intact/">IntAct database</a>. It is updated at every <a href="http://www.uniprot.org/help/synchronization">UniProt release</a>.<p><a href='/help/binary_interactions' target='_top'>More...</a></p>Binary interactionsi
Show more detailsHide detailsP01889
GO - Molecular functioni
- chaperone binding Source: UniProtKBInferred from physical interactioni
- "Major histocompatibility complex class I molecules expressed with monoglucosylated N-linked glycans bind calreticulin independently of their assembly status."
Wearsch P.A., Jakob C.A., Vallin A., Dwek R.A., Rudd P.M., Cresswell P.
J Biol Chem 279:25112-25121(2004) [PubMed] [Europe PMC] [Abstract]
- signaling receptor binding Source: UniProtKBInferred from physical interactioni
- "Human natural killer cell receptors for HLA-class I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B alleles."
Moretta A., Vitale M., Sivori S., Bottino C., Morelli L., Augugliaro R., Barbaresi M., Pende D., Ciccone E., Lopez-Botet M., Moretta L.
J Exp Med 180:545-555(1994) [PubMed] [Europe PMC] [Abstract]
- TAP binding Source: UniProtKBInferred from direct assayi
- "Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing."
Neisig A., Wubbolts R., Zang X., Melief C., Neefjes J.
J Immunol 156:3196-3206(1996) [PubMed] [Europe PMC] [Abstract]
Protein-protein interaction databases
The Biological General Repository for Interaction Datasets (BioGRID) More...BioGRIDi | 109351, 125 interactors |
Protein interaction database and analysis system More...IntActi | P01889, 89 interactors |
Molecular INTeraction database More...MINTi | P01889 |
<p>This section provides information on the tertiary and secondary structure of a protein.<p><a href='/help/structure_section' target='_top'>More...</a></p>Structurei
Secondary structure
Legend: HelixTurnBeta strandPDB Structure known for this area
Show more detailsHide details| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the <a href="http://www.uniprot.org/help/structure%5Fsection">'Structure'</a> section is used to indicate the positions of experimentally determined beta strands within the protein sequence.<p><a href='/help/strand' target='_top'>More...</a></p>Beta strandi | 27 – 36 | Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0007744">More...</a></p> Manual assertion inferred from combination of experimental and computational evidencei | 10 | |
| Beta strandi | 41 – 43 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Beta strandi | 45 – 52 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 8 | |
| Beta strandi | 55 – 61 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 7 | |
| Beta strandi | 64 – 66 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| <p>This subsection of the <a href="http://www.uniprot.org/help/structure%5Fsection">'Structure'</a> section is used to indicate the positions of experimentally determined hydrogen-bonded turns within the protein sequence. These elements correspond to the DSSP secondary structure code 'T'.<p><a href='/help/turn' target='_top'>More...</a></p>Turni | 67 – 69 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Beta strandi | 70 – 73 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 4 | |
| <p>This subsection of the <a href="http://www.uniprot.org/help/structure%5Fsection">'Structure'</a> section is used to indicate the positions of experimentally determined helical regions within the protein sequence.<p><a href='/help/helix' target='_top'>More...</a></p>Helixi | 74 – 76 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Helixi | 77 – 79 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Helixi | 81 – 108 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 28 | |
| Beta strandi | 113 – 115 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Beta strandi | 118 – 127 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 10 | |
| Beta strandi | 129 – 131 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Beta strandi | 133 – 142 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 10 | |
| Beta strandi | 145 – 150 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 6 | |
| Beta strandi | 157 – 161 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 5 | |
| Helixi | 162 – 173 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 12 | |
| Helixi | 176 – 185 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 10 | |
| Helixi | 187 – 198 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 12 | |
| Turni | 199 – 204 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 6 | |
| Beta strandi | 210 – 219 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 10 | |
| Beta strandi | 222 – 235 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 14 | |
| Beta strandi | 238 – 243 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 6 | |
| Beta strandi | 246 – 248 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Helixi | 249 – 251 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Beta strandi | 252 – 254 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Beta strandi | 261 – 263 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Beta strandi | 265 – 274 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 10 | |
| Turni | 275 – 277 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Helixi | 278 – 280 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Beta strandi | 281 – 286 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 6 | |
| Beta strandi | 290 – 292 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 | |
| Beta strandi | 294 – 296 | Combined sources Manual assertion inferred from combination of experimental and computational evidencei | 3 |
3D structure databases
SWISS-MODEL Repository - a database of annotated 3D protein structure models More...SMRi | P01889 |
Database of comparative protein structure models More...ModBasei | Search... |
Protein Data Bank in Europe - Knowledge Base More...PDBe-KBi | Search... |
<p>This section provides information on sequence similarities with other proteins and the domain(s) present in a protein.<p><a href='/help/family_and_domains_section' target='_top'>More...</a></p>Family & Domainsi
Domains and Repeats
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the <a href="http://www.uniprot.org/help/family%5Fand%5Fdomains%5Fsection">Family and Domains</a> section describes the position and type of a domain, which is defined as a specific combination of secondary structures organized into a characteristic three-dimensional structure or fold.<p><a href='/help/domain' target='_top'>More...</a></p>Domaini | 209 – 295 | Ig-like C1-typeAdd BLAST | 87 |
Region
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the 'Family and Domains' section describes a region of interest that cannot be described in other subsections.<p><a href='/help/region' target='_top'>More...</a></p>Regioni | 25 – 114 | Alpha-1Sequence analysisAdd BLAST | 90 | |
| Regioni | 115 – 206 | Alpha-2Sequence analysisAdd BLAST | 92 | |
| Regioni | 207 – 298 | Alpha-3Sequence analysisAdd BLAST | 92 | |
| Regioni | 299 – 309 | Connecting peptideSequence analysisAdd BLAST | 11 |
Motif
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the 'Family and Domains' section describes a short (usually not more than 20 amino acids) conserved sequence motif of biological significance.<p><a href='/help/motif' target='_top'>More...</a></p>Motifi | 101 – 107 | Bw6 motif1 Publication Manual assertion based on experiment ini
| 7 |
<p>This subsection of the 'Family and domains' section provides general information on the biological role of a domain. The term 'domain' is intended here in its wide acceptation, it may be a structural domain, a transmembrane region or a functional domain. Several domains are described in this subsection.<p><a href='/help/domain_cc' target='_top'>More...</a></p>Domaini
The alpha-1 domain is a structural part of the peptide-binding cleft (PubMed:25808313). Residues 101-107 determine Bw4/Bw6 motifs, which serologically distinguish HLA-B alleles. Each HLA-B allele posseses either the Bw4 or Bw6 motif. Only HLA-B alleles bearing the Bw4 epitope are recognized by NK cell inhibitory receptor KIR3DL1 (PubMed:25480565, PubMed:22020283).3 Publications
Manual assertion based on experiment ini
- Ref.72"The interaction of KIR3DL1*001 with HLA class I molecules is dependent upon molecular microarchitecture within the Bw4 epitope."
Saunders P.M., Vivian J.P., Baschuk N., Beddoe T., Widjaja J., O'Connor G.M., Hitchen C., Pymm P., Andrews D.M., Gras S., McVicar D.W., Rossjohn J., Brooks A.G.
J. Immunol. 194:781-789(2015) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES B*08:01 AND B*57:01), DOMAIN, BW4 AND BW6 MOTIFS, INTERACTION WITH KIR3DL1, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS ILE-104 AND ARG-107. - Ref.79"Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B."
Vivian J.P., Duncan R.C., Berry R., O'Connor G.M., Reid H.H., Beddoe T., Gras S., Saunders P.M., Olshina M.A., Widjaja J.M., Harpur C.M., Lin J., Maloveste S.M., Price D.A., Lafont B.A., McVicar D.W., Clements C.S., Brooks A.G., Rossjohn J.
Nature 479:401-405(2011) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 25-299 (ALLELE B*57:01) IN COMPLEX WITH B2M AND SELF-PEPTIDE, INTERACTION WITH KIR3DL1, DOMAIN, BW4 MOTIF, FUNCTION (ALLELE B*57:01). - Ref.81"A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape."
Kloverpris H.N., Cole D.K., Fuller A., Carlson J., Beck K., Schauenburg A.J., Rizkallah P.J., Buus S., Sewell A.K., Goulder P.
Retrovirology 12:20-20(2015) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.59 ANGSTROMS) OF 25-300 (ALLELE B*07:02) IN COMPLEX WITH B2M AND HIV-1 PEPTIDES, DISULFIDE BOND, FUNCTION (ALLELE B*07:02), DOMAIN.
The alpha-2 domain is a structural part of the peptide-binding cleft (PubMed:25808313). Mediates the interaction with TAP1-TAP2 complex (By similarity).By similarity
<p>Manually curated information which has been propagated from a related experimentally characterized protein.</p> <p><a href="/manual/evidences#ECO:0000250">More...</a></p> Manual assertion inferred from sequence similarity toi
1 PublicationManual assertion based on experiment ini
- Ref.81"A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape."
Kloverpris H.N., Cole D.K., Fuller A., Carlson J., Beck K., Schauenburg A.J., Rizkallah P.J., Buus S., Sewell A.K., Goulder P.
Retrovirology 12:20-20(2015) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.59 ANGSTROMS) OF 25-300 (ALLELE B*07:02) IN COMPLEX WITH B2M AND HIV-1 PEPTIDES, DISULFIDE BOND, FUNCTION (ALLELE B*07:02), DOMAIN.
The alpha-3 Ig-like domain mediates the interaction with CD8 coreceptor.By similarity
Manual assertion inferred from sequence similarity toi
Keywords - Domaini
Signal, Transmembrane, Transmembrane helixPhylogenomic databases
evolutionary genealogy of genes: Non-supervised Orthologous Groups More...eggNOGi | ENOG502RQEK, Eukaryota |
Ensembl GeneTree More...GeneTreei | ENSGT00980000198488 |
The HOGENOM Database of Homologous Genes from Fully Sequenced Organisms More...HOGENOMi | CLU_047501_1_1_1 |
Identification of Orthologs from Complete Genome Data More...OMAi | VHEIHER |
Database of Orthologous Groups More...OrthoDBi | 651627at2759 |
Database for complete collections of gene phylogenies More...PhylomeDBi | P01889 |
TreeFam database of animal gene trees More...TreeFami | TF336617 |
Family and domain databases
Gene3D Structural and Functional Annotation of Protein Families More...Gene3Di | 2.60.40.10, 1 hit 3.30.500.10, 1 hit |
Integrated resource of protein families, domains and functional sites More...InterProi | View protein in InterPro IPR007110, Ig-like_dom IPR036179, Ig-like_dom_sf IPR013783, Ig-like_fold IPR003006, Ig/MHC_CS IPR003597, Ig_C1-set IPR011161, MHC_I-like_Ag-recog IPR037055, MHC_I-like_Ag-recog_sf IPR011162, MHC_I/II-like_Ag-recog IPR001039, MHC_I_a_a1/a2 IPR010579, MHC_I_a_C |
Pfam protein domain database More...Pfami | View protein in Pfam PF07654, C1-set, 1 hit PF00129, MHC_I, 1 hit PF06623, MHC_I_C, 1 hit |
Protein Motif fingerprint database; a protein domain database More...PRINTSi | PR01638, MHCCLASSI |
Simple Modular Architecture Research Tool; a protein domain database More...SMARTi | View protein in SMART SM00407, IGc1, 1 hit |
Superfamily database of structural and functional annotation More...SUPFAMi | SSF48726, SSF48726, 1 hit SSF54452, SSF54452, 1 hit |
<p>This section displays by default the canonical protein sequence and upon request all isoforms described in the entry. It also includes information pertinent to the sequence(s), including <a href="http://www.uniprot.org/help/sequence%5Flength">length</a> and <a href="http://www.uniprot.org/help/sequences">molecular weight</a>. The information is filed in different subsections. The current subsections and their content are listed below:<p><a href='/help/sequences_section' target='_top'>More...</a></p>Sequence (1+)i
<p>This subsection of the <a href="http://www.uniprot.org/help/sequences%5Fsection">Sequence</a> section indicates if the <a href="http://www.uniprot.org/help/canonical%5Fand%5Fisoforms">canonical sequence</a> displayed by default in the entry is complete or not.<p><a href='/help/sequence_status' target='_top'>More...</a></p>Sequence statusi: Complete.
<p>This subsection of the <a href="http://www.uniprot.org/help/sequences%5Fsection">Sequence</a> section indicates if the <a href="http://www.uniprot.org/help/canonical%5Fand%5Fisoforms">canonical sequence</a> displayed by default in the entry is in its mature form or if it represents the precursor.<p><a href='/help/sequence_processing' target='_top'>More...</a></p>Sequence processingi: The displayed sequence is further processed into a mature form.
This entry has 1 described isoform and 25 potential isoforms that are computationally mapped.Show allAlign All
P01889-1 [UniParc]FASTAAdd to basketAdded to basket
« Hide
Show »10 20 30 40 50
MLVMAPRTVL LLLSAALALT ETWAGSHSMR YFYTSVSRPG RGEPRFISVG
60 70 80 90 100
YVDDTQFVRF DSDAASPREE PRAPWIEQEG PEYWDRNTQI YKAQAQTDRE
110 120 130 140 150
SLRNLRGYYN QSEAGSHTLQ SMYGCDVGPD GRLLRGHDQY AYDGKDYIAL
160 170 180 190 200
NEDLRSWTAA DTAAQITQRK WEAAREAEQR RAYLEGECVE WLRRYLENGK
210 220 230 240 250
DKLERADPPK THVTHHPISD HEATLRCWAL GFYPAEITLT WQRDGEDQTQ
260 270 280 290 300
DTELVETRPA GDRTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP
310 320 330 340 350
SSQSTVPIVG IVAGLAVLAV VVIGAVVAAV MCRRKSSGGK GGSYSQAACS
360
DSAQGSDVSL TA
Length:362
Mass (Da):40,460
Last modified:February 1, 1991 - v3
<p>The checksum is a form of redundancy check that is calculated
from the sequence. It is useful for tracking sequence updates.</p>
<p>It should be noted that while, in theory, two different sequences could
have the same checksum value, the likelihood that this would happen
is extremely low.</p>
<p>However UniProtKB may contain entries with identical sequences in case
of multiple genes (paralogs).</p>
<p>The checksum is computed as the sequence 64-bit Cyclic Redundancy Check value (CRC64)
using the generator polynomial: x<sup>64</sup> + x<sup>4</sup> + x<sup>3</sup> + x + 1.
The algorithm is described in the ISO 3309 standard.
</p>
<p class="publication">Press W.H., Flannery B.P., Teukolsky S.A. and Vetterling W.T.<br />
<strong>Cyclic redundancy and other checksums</strong><br />
<a href="http://www.nrbook.com/b/bookcpdf.php">Numerical recipes in C 2nd ed., pp896-902, Cambridge University Press (1993)</a>)</p>
Checksum:i5E5A7BDE031403D6
<p>In eukaryotic reference proteomes, unreviewed entries that are likely to belong to the same gene are computationally mapped, based on gene identifiers from Ensembl, EnsemblGenomes and model organism databases.<p><a href='/help/gene_centric_isoform_mapping' target='_top'>More...</a></p>Computationally mapped potential isoform sequencesi
There are 25 potential isoforms mapped to this entry.BLASTAlignShow allAdd to basket| Entry | Entry name | Protein names | Gene names | Length | Annotation | ||
|---|---|---|---|---|---|---|---|
| Q2L6G2 | Q2L6G2_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen B alpha chain (HLA class I histocompatibility antigen, B alpha chain) (Leukocyte antigen (HLA) class I molecule) (Lymphocyte antigen) (MHC class I antigen) (MHC class I protein) (Major histocompatibility complex, class I, B) | HLA-B HLA-B*4403, HLA-B*44031, HLA-B*44032 | 362 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the 'correct annotation' for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| Q5SS57 | Q5SS57_HUMAN | HLA class I antigen HLA class I antigen (HLA class I histocompatibility antigen) (HLA class I histocompatibility antigen, B alpha chain) (MHC class I antigen) (MICA protein) | HLA-B MICA | 362 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the 'correct annotation' for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| S6AU73 | S6AU73_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen (HLA class I histocompatibility antigen, B alpha chain) (HLA-B*18:01:01:NEW) (MHC class I antigen) (MHC class I protein) | HLA-B HLA B | 362 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the 'correct annotation' for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| A0A1W2PPR8 | A0A1W2PPR8_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, B alpha chain | HLA-B | 363 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the 'correct annotation' for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| D5H3J5 | D5H3J5_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen B alpha chain (HLA class I histocompatibility antigen, B alpha chain) (MHC class I antigen) (MHC class I protein) | HLA-B | 362 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the 'correct annotation' for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| D9J307 | D9J307_HUMAN | HLA class I antigen HLA class I antigen (HLA class I histocompatibility antigen B alpha chain) (HLA class I histocompatibility antigen, B alpha chain) (MHC class I antigen) (MHC class I protein) (MHC class I protein (HLA-B)) | HLA-B | 362 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the 'correct annotation' for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| A0A140T9G0 | A0A140T9G0_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, B alpha chain | HLA-B | 241 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the 'correct annotation' for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| A0A140T9S9 | A0A140T9S9_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, B alpha chain | HLA-B | 241 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the 'correct annotation' for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| A0A140T951 | A0A140T951_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, B alpha chain | HLA-B | 241 | Annotation score: Annotation score:1 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the 'correct annotation' for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| A0A140T9A9 | A0A140T9A9_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, B alpha chain | HLA-B | 241 | Annotation score: Annotation score:1 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the 'correct annotation' for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| There are more potential isoformsShow all | |||||||
<p>This subsection of the 'Sequence' section provides information on polymorphic variants. If the variant is associated with a disease state, the description of the latter can be found in the <a href="http://www.uniprot.org/manual/involvement%5Fin%5Fdisease">'Involvement in disease'</a> subsection.<p><a href='/help/polymorphism' target='_top'>More...</a></p>Polymorphismi
The most polymorphic of the mammalian genome. Polymorphic residues encode for alpha-1 and alpha-2 domains of the peptide-binding cleft, where they contribute to variations in peptide binding and TCR recognition among different alleles. The human population is estimated to have millions of HLA-B alleles. But only 17 common HLA-A alleles are considered core alleles, representing all functionally significant variation (polymorphism) in alpha-1 and alpha-2 domains. These are: B*07:02; B*08:01; B*13:02; B*15:01; B*18:01; B*27:05; B*35:01; B*37:01; B*38:01; B*40:01; B*44:02; B*45:01; B*51:01; B*54:01; B*57:01 and B*73:01. Among these, B*07:02; B*15:01; B*18:01; B*37:01; B*51:01; B*54:01; B*57:01 and B*73:01, were likely passed by introgression from archaic to modern humans. Functional alleles of more recent origin (non-core) were derived by recombination (PubMed:28650991). The sequence shown is that of B*07:02. The sequences of core alleles and common representative alleles of serologically distinct allele groups are described as variants of B*07:02.1 Publication
Manual assertion based on experiment ini
- Ref.88"Distinguishing functional polymorphism from random variation in the sequences of >10,000 HLA-A, -B and -C alleles."
Robinson J., Guethlein L.A., Cereb N., Yang S.Y., Norman P.J., Marsh S.G.E., Parham P.
PLoS Genet. 13:E1006862-E1006862(2017) [PubMed] [Europe PMC] [Abstract]Cited for: POLYMORPHISM.
Natural variant
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the 'Sequence' section describes natural variant(s) of the protein sequence.<p><a href='/help/variant' target='_top'>More...</a></p>Natural variantiVAR_082483 | 2 | L → R in allele B*13:02, allele B*15:01, allele B*18:01, allele B*27:01, allele B*27:05, allele B*35:01, allele B*37:01, allele B*40:01, allele B*40:02, allele B*41:01, allele B*44:02, allele B*45:01, allele B*46:01, allele B*47:01, allele B*49:01, allele B*50:01, allele B*51:01, allele B*52:01, allele B*53:01, allele B*54:01, allele B*55:01, allele B*56:01, allele B*57:01, allele B*58:01, allele B*59:01, allele B*78:01 and allele B*82:01. 34 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082484 | 4 | M → T in allele B*13:02, allele B*15:01, allele B*18:01, allele B*27:01, allele B*27:05, allele B*35:01, allele B*37:01, allele B*40:01, allele B*40:02, allele B*41:01, allele B*44:02, allele B*45:01, allele B*46:01, allele B*47:01, allele B*49:01, allele B*50:01, allele B*51:01, allele B*52:01, allele B*53:01, allele B*54:01, allele B*55:01, allele B*56:01, allele B*57:01, allele B*58:01, allele B*59:01, allele B*78:01 and allele B*82:01. 34 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082485 | 9 | V → L in allele B*13:02, allele B*18:01, allele B*27:01, allele B*27:05, allele B*37:01, allele B*40:02, allele B*44:02, allele B*47:01, allele B*54:01, allele B*55:01, allele B*56:01, allele B*59:01 and allele B*82:01. 16 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082486 | 14 | S → W in allele B*13:02, allele B*18:01, allele B*27:01, allele B*27:05, allele B*35:01, allele B*37:01, allele B*40:02, allele B*44:02, allele B*47:01, allele B*51:01, allele B*52:01, allele B*53:01, allele B*54:01, allele B*55:01, allele B*56:01, allele B*57:01, allele B*58:01, allele B*59:01, allele B*78:01, allele B*81:01 and allele B*82:01. 30 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082487 | 15 | A → G in allele B*13:02, allele B*15:01, allele B*18:01, allele B*27:01, allele B*27:05, allele B*35:01, allele B*37:01, allele B*40:02, allele B*44:02, allele B*46:01, allele B*47:01, allele B*51:01, allele B*52:01, allele B*53:01, allele B*54:01, allele B*55:01, allele B*56:01, allele B*57:01, allele B*58:01, allele B*59:01, allele B*78:01, allele B*81:01 and allele B*82:01. 33 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082488 | 17 | L → V in allele B*13:02, allele B*18:01, allele B*27:01, allele B*27:05, allele B*35:01, allele B*37:01, allele B*40:02, allele B*44:02, allele B*47:01, allele B*51:01, allele B*52:01, allele B*53:01, allele B*57:01, allele B*58:01, allele B*78:01 and allele B*81:01. 24 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082489 | 33 | Y → D in allele B*08:01; associated with increased risk for rheumatoid arthritis. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082490 | 33 | Y → H in allele B*18:01, allele B*27:01, allele B*27:05, allele B*37:01, allele B*40:01, allele B*40:02, allele B*41:01, allele B*45:01, allele B*49:01, allele B*50:01 and allele B*73:01. 18 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082491 | 35 | S → A in allele B*08:01, allele B*13:02, allele B*15:01, allele B*35:01, allele B*40:01, allele B*41:01, allele B*44:02, allele B*45:01, allele B*46:01, allele B*47:01, allele B*49:01, allele B*50:01, allele B*51:01, allele B*52:01, allele B*53:01, allele B*54:01, allele B*55:01, allele B*56:01, allele B*57:01, allele B*58:01, allele B*59:01, allele B*78:01 and allele B*82:01. 30 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082492 | 36 | V → M in allele B*08:01, allele B*13:02, allele B*15:01, allele B*35:01, allele B*40:01, allele B*41:01, allele B*44:02, allele B*45:01, allele B*46:01, allele B*47:01, allele B*49:01, allele B*50:01, allele B*51:01, allele B*52:01, allele B*53:01, allele B*54:01, allele B*55:01, allele B*56:01, allele B*57:01, allele B*58:01, allele B*59:01, allele B*78:01 and allele B*82:01. 30 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082493 | 48 | S → A in allele B*15:01, allele B*35:01, allele B*46:01, allele B*51:01, allele B*52:01, allele B*53:01, allele B*54:01, allele B*55:01, allele B*56:01, allele B*57:01, allele B*58:01, allele B*59:01 and allele B*78:01. 20 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082494 | 48 | S → T in allele B*13:02, allele B*27:01, allele B*27:05, allele B*40:01, allele B*40:02, allele B*41:01, allele B*44:02, allele B*45:01, allele B*47:01, allele B*49:01, allele B*50:01 and allele B*73:01. 19 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082495 | 54 | D → G in allele B*18:01. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082496 | 56 | Q → L in allele B*27:01, allele B*27:05, allele B*40:01, allele B*40:02, allele B*41:01, allele B*44:02, allele B*45:01, allele B*47:01, allele B*49:01 and allele B*50:01. 14 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082497 | 65 | A → T in allele B*13:02, allele B*40:01, allele B*40:02, allele B*41:01, allele B*44:02, allele B*45:01, allele B*47:01, allele B*49:01 and allele B*50:01. 12 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082498 | 69 | E → G in allele B*54:01. 1 Publication Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082499 | 69 | E → K in allele B*40:01, allele B*40:02, allele B*41:01, allele B*44:02, allele B*45:01, allele B*47:01, allele B*49:01 and allele B*50:01. 11 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082500 | 69 | E → M in allele B*13:02, allele B*15:01, allele B*46:01 and allele B*57:01; requires 2 nucleotide substitutions. 8 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082501 | 69 | E → T in allele B*18:01, allele B*35:01, allele B*37:01, allele B*51:01, allele B*52:01, allele B*53:01, allele B*58:01 and allele B*78:01; requires 2 nucleotide substitutions. 13 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082502 | 70 | E → A in allele B*13:02, allele B*15:01, allele B*46:01 and allele B*57:01. 8 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082503 | 76 | I → V in allele B*54:01. 1 Publication Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082504 | 86 | R → G in allele B*57:01 and allele B*58:01. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082505 | 87 | N → E in allele B*13:02, allele B*15:01, allele B*27:01, allele B*27:05, allele B*37:01, allele B*39:02, allele B*40:01, allele B*40:02, allele B*41:01, allele B*44:02, allele B*45:01, allele B*46:01, allele B*47:01, allele B*48:01, allele B*49:01, allele B*50:01, allele B*52:01, allele B*57:01 and allele B*58:01; requires 2 nucleotide substitutions. 27 Publications Manual assertion based on experiment ini
|